RT Journal Article
SR Electronic
T1 Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.19.23290216
DO 10.1101/2023.05.19.23290216
A1 Frei, Anja L
A1 McGuigan, Anthony
A1 Sinha, Ritik RAK
A1 Glaire, Mark A
A1 Jabbar, Faiz
A1 Gneo, Luciana
A1 Tomasevic, Tijana
A1 Harkin, Andrea
A1 Iveson, Tim J
A1 Saunders, Mark
A1 Oein, Karin
A1 Maka, Noori
A1 Pezella, Francesco
A1 Campo, Leticia
A1 Hay, Jennifer
A1 Edwards, Joanne
A1 Sansom, Owen
A1 Kelly, Caroline
A1 Tomlinson, Ian
A1 Kildal, Wanja
A1 Kerr, Rachel S
A1 Kerr, David J
A1 Danielsen, Håvard E
A1 Domingo, Enric
A1 TransSCOT consortium
A1 Church, David N
A1 Koelzer, Viktor H
YR 2023
UL http://medrxiv.org/content/early/2023/08/16/2023.05.19.23290216.abstract
AB Multiplex immunofluorescence (mIF) imaging can provide comprehensive quantitative and spatial information for multiple immune markers for tumour immunoprofiling. However, application at scale to clinical trial samples sourced from multiple institutions is challenging due to pre-analytical heterogeneity. This study reports an analytical approach to the largest multiparameter immunoprofiling study of clinical trial samples to date. We analysed 12,592 tissue microarray (TMA) spots from 3,545 colorectal cancers (CRC) sourced from more than 240 institutions in two clinical trials (QUASAR 2 and SCOT) stained for CD4, CD8, CD20, CD68, FoxP3, pan-cytokeratin and DAPI by mIF. TMA slides were multi-spectrally imaged and analysed by cell-based and pixel-based marker analysis. We developed an adaptive thresholding method to account for inter- and intra-slide intensity variation in TMA analysis. Applying this method effectively ameliorated inter- and intra-slide intensity variation improving the image analysis results compared to methods using a single global threshold. Correlation of CD8 data derived by our mIF analysis approach with single-plex chromogenic immunohistochemistry (IHC) CD8 data derived from subsequent sections indicates the validity of our method (Spearman’s rank correlation coefficients ρ between 0.63 and 0.66, p-value ≪ 0.01) as compared to current gold standard analysis approach. Evaluation of correlation between cell-based and pixel-based analysis results confirms equivalency (ρ > 0.8, p ≪ 0.01, except for CD20 in epithelium region) of both analytical approaches. These data suggests that our adaptive thresholding approach can enable analysis of mIF-stained clinical trial TMA datasets by digital pathology at scale for precision immunoprofiling.Competing Interest StatementDNC has participated in advisory boards for MSD and has received research funding on behalf of the TransSCOT consortium from HalioDx for analyses independent of this study. VHK has served as an invited speaker on behalf of Indica Labs and Sharing Progress in Cancer Care (SPCC), is on an advisory board of Takeda and has received project-based research funding from The Image Analysis Group and Roche outside of the submitted work. All other authors declare no competing interests.Funding StatementThe SCOT trial was funded by the Medical Research Council (transferred to NETSCC - Efficacy and Mechanism Evaluation) (Grant Ref: G0601705), the NIHR Health Technology Assessment Programme (Grant Ref: 14/140/84), Cancer Research UK (CRUK) Core Clinical Trials Unit Glasgow Funding (Funding Ref: C6716/A9894), and the Swedish Cancer Society. The TransSCOT sample collection was funded by a CRUK Clinical Trials Awards and Advisory Committee - Sample Collection (Grant Ref: C6716/A13941). The QUASAR2 trial was funded by an unrestricted educational grant to DJK from Roche. This study was funded by the Oxford NIHR Comprehensive Biomedical Research Centre, a CRUK Advanced Clinician Scientist Fellowship (Ref: C26642/A27963) to DNC, a CRUK award (Ref: A25142) to the CRUK Glasgow Centre and core funding to VHK by the University of Zurich. VHK acknowledges funding by the Promedica Foundation (Ref: F-87701-41-01). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for patient recruitment and sample collection in the SCOT and QUASAR 2 trial was obtained centrally and at all recruiting centres (REC reference number 07/S0703/136 and 04/MRE/11/18). Ethical approval for anonymised tumour molecular analysis was granted by Oxfordshire Research Ethics Committee B (REC 05\Q1605\66).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets pertaining to the SCOT trial used during the current study are available from the TransSCOT collaboration on reasonable request. Applications for analysis of TransSCOT samples are welcome and should be addressed to JH: Jennifer.Hay{at}glasgow.ac.uk. Datasets and samples from the QUASAR2 trial are available upon reasonable request and should be addressed to DNC: david.church{at}well.ox.ac.ukCRCcolorectal cancerIFimmunofluorescenceIHCimmunohistochemistrymIFmultiplex immunofluorescenceQCquality controlQ2QUASAR 2SITCSociety for Immunotherapy of CancerTMAtissue microarrayWSIwhole slide image